Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 8.2.2023Teva B.V. (TEV-NL-4)05175Olanzapin Actavis 10 mg filmom obalené tablety (tbl flm 56x10 mg (blis.Al/Al))15.1.2023R
 8.2.2023Teva B.V. (TEV-NL-4)09530Ramipril H 5 mg/25 mg Actavis (tbl 30x5 mg/25 mg (blis.Al/Al))20.1.2023R
 8.2.2023Teva B.V. (TEV-NL-4)1626CEzetimib/simvastatín Teva B.V. 10 mg/40 mg (tbl 30x10 mg/40 mg (blis.OPA/Al/PVC/Al))12.1.2023O
 8.2.2023Teva B.V. (TEV-NL-4)1627CEzetimib/simvastatín Teva B.V. 10 mg/40 mg (tbl 100x10 mg/40 mg (blis.OPA/Al/PVC/Al))11.1.2023U
 8.2.2023Teva B.V. (TEV-NL-4)36701STOPTUSSIN tablety (tbl 1x20 (blis.Al/PVC))1.2.2023R
 8.2.2023Teva B.V. (TEV-NL-4)62864Candibene (aer deo 1x40 ml/400 mg (fľ.skl.hnedá))23.1.2023R
 8.2.2023Teva B.V. (TEV-NL-4)66180Valsartan HCT Teva 160/25 mg (tbl flm 28x160 mg/25 mg (blis.PVC/PE/PVDC/Al))20.1.2023R
 8.2.2023Teva B.V. (TEV-NL-4)94920Ambrobene 7,5 mg/ml (sol pin 1x100 ml/750 mg (liek.skl.hnedá))6.2.2023R
 8.2.2023Teva B.V. (TEV-NL-4)35950Betahistin Actavis 8 mg (tbl 100x8 mg)15.4.2023R
 8.2.2023Teva B.V. (TEV-NL-4)4961BBrieka 150 mg (cps dur 56x150 mg (blis.Al/PVC))15.4.2023R
 8.2.2023Teva B.V. (TEV-NL-4)76660Neotigason 10 mg (cps dur 30x10 mg (blis.PVC/PVDC))15.3.2023R
 8.2.2023TEVA Pharmaceuticals Slovakia s.r.o. (TEV-SK)37256Cabest 0,5 mg (tbl 8x0,5 mg (fľ.skl.hnedá))8.2.2023O
 8.2.2023Bayer AG (BAY)9845DKerendia 20 mg filmom obalené tablety (tbl flm 28x20 mg (blis.PVC/PVDC/Al))8.2.2023U
 8.2.2023Bayer AG (BAY)9840DKerendia 10 mg filmom obalené tablety (tbl flm 28x10 mg (blis.PVC/PVDC/Al))8.2.2023U
 8.2.2023Fresenius Kabi s.r.o. (FRK-CZ-3)58728Ciprofloxacin Kabi 200 mg/100 ml (sol inf 1x100 ml/200 mg (fľ.PE))31.8.2021Z

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)